2022 World Conference on Lung Cancer (ePosters)-EP08.01-109. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

EP08.01-109. TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

Back to course

Pdf Summary

A phase II study investigated the combination of eftilagimod alpha (efti), a soluble LAG-3 protein, and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients. Efti acts as an MHC class II agonist, targeting a subset of MHC class II molecules to activate antigen presenting cells (APCs), natural killer (NK) cells, and T-cells. The study included 36 patients with limited treatment options, with 75% having low PD-L1 expression and 67% having received doublet chemotherapy and anti-PD-1 treatment previously. The results showed a confirmed objective response rate (ORR) of 5.6% and disease control rate (DCR) of 36.1% according to iRECIST. Additionally, 25% of patients had disease control at 6 months, with a median progression-free survival (PFS) of 2.1 months. The overall survival (OS) rates were 72% at 6 months and 37% at 18 months, with a median OS of 9.7 months. The combination of efti and pembrolizumab was well tolerated, with no new safety signals identified. The study supports further investigation of efti and pembrolizumab in PD-X refractory patients. The combination therapy showed promising anti-tumor activity and may offer a treatment option for patients who have progressed on anti-PD-1/PD-L1 therapy.

Asset Subtitle

Martin Forster

Meta Tag

Speaker Martin Forster

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

eftilagimod alpha

pembrolizumab

PD-1/PD-L1 refractory

metastatic non-small cell lung carcinoma

MHC class II agonist

iRECIST

progression-free survival

overall survival rates

combination therapy

anti-tumor activity